Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Sertraline is an antidepressant that works by increasing the amount of serotonin available in the brain. Serotonin is a chemical messenger involved in mood, anxiety, and other mental states. Laboratory studies show that sertraline is selective—it blocks the reabsorption of serotonin strongly, but has only very weak effects on other brain chemicals like noradrenaline and dopamine.
It is approved in Australia for several conditions: major depression, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. For children and adolescents aged six and older, it can be used specifically to treat OCD. Sertraline stays in the body for about 26 hours on average after a dose, which is why it is usually taken once a day.
Side effects your family member might notice include trouble sleeping, tremor, drowsiness, dizziness, diarrhoea, nausea, fatigue, and headache. More serious risks have been reported, though the source data does not specify how often they occur. These include neuroleptic malignant syndrome (a severe reaction involving muscle rigidity and high fever), worsening of suicidal thoughts, heart rhythm changes (QTc prolongation and a dangerous rhythm called torsade de pointes), serious liver problems such as hepatitis or jaundice, and severe skin reactions like Stevens-Johnson syndrome.
Sertraline should not be taken by anyone allergic to it, anyone taking the medication pimozide, or anyone taking a type of antidepressant called an MAOI. If your family member has recently stopped an MAOI, at least 14 days must pass before starting sertraline; the same waiting period applies if switching from sertraline to an MAOI. Sertraline can affect the liver enzymes that break down other medications—particularly an enzyme called CYP2D6. At lower doses this effect is less pronounced than with some other antidepressants, but it can still lead to interactions with other drugs.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationMajor depressive disorders Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
Obsessive-compulsive disorder Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
“In vitro studies have also suggested that sertraline is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on noradrenaline and dopamine neuronal reuptake.”
“The average terminal elimination half-life of plasma sertraline is about 26 hours.”
“There is variability among antidepressants in the extent to which they inhibit the activity of isozyme CYP2D6, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Sertraline is a selective serotonin reuptake inhibitor that potently and selectively inhibits neuronal serotonin reuptake, with only very weak effects on noradrenaline and dopamine reuptake. TGA-approved indications include major depressive disorder, obsessive–compulsive disorder (in adults and children aged six years and older), panic disorder, social anxiety disorder and its relapse prevention, and premenstrual dysphoric disorder as defined by DSM-IV criteria.
The average terminal elimination half-life is approximately 26 hours. Sertraline exhibits dose-dependent inhibition of CYP2D6; at lower doses the inhibitory effect is less prominent than with some other agents in the class, but clinically important 2D6 inhibition remains possible. Concomitant use with pimozide is contraindicated, as is use with or within 14 days of a monoamine oxidase inhibitor. Sertraline is contraindicated in patients with known hypersensitivity to the drug. Common adverse effects include insomnia, tremor, somnolence, dizziness, diarrhoea, nausea, fatigue, and headache. Serious but less frequent risks include neuroleptic malignant syndrome, suicidal ideation, QTc prolongation and torsade de pointes, serious hepatic events (including hepatitis, jaundice, and liver failure), and rare exfoliative skin disorders such as Stevens–Johnson syndrome and toxic epidermal necrolysis.
Working under the parallel aged-care framework? Aged-care equivalent →
Panic disorder Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The treatment must be for use when other treatments have failed; OR The treatment must be for use when other treatments are inappropriate.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.